Farther Finance Advisors’s AIM ImmunoTech AIM Stock Holding History

Farther Finance Advisors’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	1	–	–	﹤0.01%	6163
2026 Q1	$1	Hold	1	–	–	﹤0.01%	5752
2025 Q4	$1	Hold	1	–	–	﹤0.01%	5451
2025 Q3	$3	Hold	1	–	–	﹤0.01%	4945
2025 Q2	$9	Sell	1 -1	-50%	-$10	﹤0.01%	4460
2025 Q1	$19	Hold	2	–	–	﹤0.01%	4194
2024 Q4	$30	Hold	2	–	–	﹤0.01%	3913
2024 Q3	$41	Buy	+2	New	+$67	﹤0.01%	3878

Other funds holding AIM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GSC

Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Farther Finance Advisors's AIM Position: Q2 2026 in Review

Farther Finance Advisors held its AIM ImmunoTech (AIM) position steady in Q2 2026 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6163.

Farther Finance Advisors first reported a position in AIM in Q3 2024 and has held it in 8 quarters since. The position peaked at $41 in Q3 2024. 18 funds tracked by Wall St. Rank hold AIM as of Q2 2026.

Farther Finance Advisors held 1 share of AIM ImmunoTech worth $0 as of Q2 2026.
Farther Finance Advisors left its AIM ImmunoTech share count unchanged in Q2 2026.
AIM ImmunoTech made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #6163 holding.
Farther Finance Advisors first reported a position in AIM ImmunoTech in Q3 2024 and has held it in 8 quarters since.
Farther Finance Advisors's AIM ImmunoTech position peaked at $41 in Q3 2024.
18 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.